Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
– – BMB-101 is ahighly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders. – – qEEG study was conducted in healthy individuals in Cohort 4 of the Multiple Ascending Dose arm of the study. – – Proof of Mechanism…
